Prelude Therapeutics IncorporatedPRLDNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank100
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P100
Near historical high
vs 2Y Ago
27x
Strong expansion
Streak
3 qtr
Consecutive growthAccelerating
PeriodValue
Q4 2025220.95%
Q3 202526.69%
Q2 202523.83%
Q1 2025-65.02%
Q4 202424.00%
Q3 2024-18.38%
Q2 202427.47%
Q1 2024-34.83%
Q4 20238.20%
Q3 20237.17%
Q2 20238.18%
Q1 2023-31.43%
Q4 2022-12.17%
Q3 2022-10.67%
Q2 202215.65%
Q1 202214.81%
Q4 2021-18.04%
Q3 2021-9.35%
Q2 2021-23.35%
Q1 2021-8.73%
Q4 2020-18.71%
Q3 2020-40.50%
Q2 202010.27%
Q1 2020-17.14%
Q4 2019-50.45%
Q3 2019-97228.61%
Q2 20190.00%
Q1 20190.00%